Vericel Corporation VCEL R2K
Healthcare · Biotechnology · United States
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
READ MORE ›$33.33
-19.30% 1Y
Market & Price
Market Cap
$1.70B
Current Price
$33.33
High / Low (52W)
$45.70 / $29.34
Beta
1.16
Valuation
Stock P/E
77.51
Industry PE
23.65
Forward P/E
39.12
PEG Ratio
-
Book Value
$6.98
Price to Book
4.77
P/S
5.83
EV/EBITDA
59.21
Dividend Yield
-
Profitability & Returns
ROCE
4.10%
ROE
6.59%
ROA
2.17%
Profit Margin
7.35%
Op Margin
-11.79%
EPS (Latest Qtr)
$-0.12
EPS (TTM)
$0.43
Balance Sheet & Liquidity
Debt/Equity
0.27
Quick Ratio
4.62
Current Ratio
5.18
Debt
$95.04M
Total Assets
$487.97M
Current Assets
$247.44M
Working Capital
$198.29M
Ownership
Promoter Holding
1.20%
Chg in Prom Hold
-
FII / Inst Holding
111.21%
Chg in FII Hold
-0.00%
Financial Snapshot
Enterprise Value
$1.65B
Total Revenue (TTM)
$292.09M
EBITDA
$27.90M
Free Cash Flow
$42.37M
Operating Cash Flow
$61.69M
Shares Outstanding
51.07M
Gross Margin
74.84%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
18.90%
Profit 5Y
66.29%
Revenue (YoY)
30.10%
Earnings (YoY)
-
PROS
- Compounding revenue at 18.9% over 5 years.
- Profit CAGR of 66.3% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 77.5.
- Trading 27.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VCEL Vericel Corporation R2K | 33.33 | 77.51 | $1.70B | - | 4.10% | 6.59% | 18.90% | 66.29% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 9.36M | 16.95M | 14.26M | - | 18.03M | 19.01M | 22.48M | 31.34M | 21.81M | 26.15M | 30.50M | 39.39M | 26.68M | 20.01M | 31.02M | - | 33.63M | 38.68M | 33.72M | 35.85M | 36.83M | 38.33M | 41.02M | 45.92M | 45.58M | 51.28M | 52.66M | - | - | 52.60M | 63.24M | 67.50M | 92.92M | 68.42M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.32M | 16.63M | 17.92M | 19.79M | 19.16M |
| Gross Profit | 4.54M | 8.19M | 7.55M | 5.52M | 4.07M | 14.96M | 2.25M | 9.28M | 7.07M | 14.96M | 10.36M | 11.28M | 14.35M | 22.71M | 13.17M | 17.13M | 21.18M | 28.80M | 16.76M | 11.35M | 22.47M | 33.65M | 22.98M | 26.91M | 22.10M | 23.45M | 22.85M | 25.23M | 26.52M | 29.94M | 30.61M | 35.35M | 36.60M | - | - | 36.27M | 46.61M | 49.59M | 73.13M | 49.27M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.06M | 48.64M | 46.13M | 50.71M | 57.33M |
| Operating Income | -4.88M | -4.96M | -1.99M | -4.98M | -6.38M | 1.19M | -9.62M | -2.52M | -4.03M | 1.19M | -4.32M | -4.25M | -1.34M | 6.00M | -3.36M | -20.20M | 3.10M | 9.21M | -5.08M | -8.36M | 3.52M | 12.29M | -3.31M | -3.73M | -4.96M | -7.27M | -9.08M | -6.79M | -8.18M | -5.96M | -5.06M | -5.46M | -6.03M | - | - | -12.79M | -2.03M | 3.45M | 22.41M | -8.06M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.41M | 2.43M | 8.18M | 27.35M | -2.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 153.00K | 157.00K | 158.00K | 162.00K | 160.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.25M | -553.00K | 5.07M | 24.10M | -6.30M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 148.00K | - | - | - | - | - |
| Net Income | -4.42M | -4.91M | -3.65M | -3.04M | -6.67M | 287.00K | -9.78M | -2.39M | -5.41M | 287.00K | -7.66M | -4.65M | -1.07M | 5.24M | -2.84M | -19.79M | 3.47M | 9.50M | -4.71M | -8.27M | 3.62M | 12.22M | -3.29M | -3.79M | -4.93M | -7.09M | -8.96M | -6.58M | -7.50M | -5.02M | -3.66M | -3.86M | -4.68M | - | - | -11.25M | -553.00K | 5.07M | 23.24M | -6.30M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.21 | -0.12 | -0.02 | 0.11 | -0.07 | -0.45 | 0.07 | 0.20 | -0.10 | -0.18 | 0.08 | 0.25 | -0.07 | -0.08 | -0.11 | -0.15 | -0.19 | -0.14 | -0.16 | -0.11 | -0.08 | -0.08 | -0.10 | - | - | -0.23 | -0.01 | 0.10 | 0.45 | -0.12 |
| R&D Expense | 3.74M | - | 3.54M | 4.06M | 3.44M | - | 3.47M | 2.97M | 2.92M | - | 3.73M | 3.74M | 3.11M | - | 3.01M | 21.07M | 3.10M | - | 3.76M | 3.23M | 2.91M | - | 3.63M | 4.45M | 4.28M | 4.86M | 4.79M | 5.05M | 5.21M | 5.25M | 5.68M | 6.42M | 7.36M | 6.09M | - | 7.26M | 6.73M | 6.32M | - | 8.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 54.38M | 62.76M | 90.86M | 117.85M | 121.97M | - | 164.37M | 197.52M | 237.22M | 276.26M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.58M | 61.94M | 65.12M | 70.66M |
| Gross Profit | - | - | - | 15.00K | 15.00K | 11.50M | 24.70M | 26.08M | 33.57M | 58.70M | 80.28M | 84.23M | - | 109.79M | 135.58M | 172.11M | 205.60M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 126.85M | 142.04M | 167.59M | 194.56M |
| Operating Income | -16.17M | -17.80M | -29.04M | -33.76M | -20.96M | -23.53M | -16.67M | -19.25M | -14.98M | -3.91M | -11.25M | 2.37M | - | -17.06M | -6.46M | 4.52M | 11.04M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.64M | 2.86M | 16.63M | 29.55M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 366.00K | 600.00K | 614.00K | 630.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.99M | -2.37M | 10.51M | 17.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 721.00K | 814.00K | 148.00K | 859.00K |
| Net Income | - | -14.56M | -19.67M | -29.47M | -15.62M | -19.92M | -16.34M | -19.57M | -17.29M | -8.14M | -9.66M | 2.86M | - | -16.71M | -3.18M | 10.36M | 16.52M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.20 | -0.22 | 0.06 | -0.16 | -0.35 | -0.07 | 0.20 | - |
| R&D Expense | 11.29M | 12.66M | 21.33M | 26.02M | 15.10M | 21.26M | 18.89M | 15.29M | 12.94M | 13.60M | 30.39M | 13.02M | 16.29M | 19.94M | 21.04M | 24.80M | 27.56M |
Compounded Sales Growth
| 5 Years: | 18.90% |
| 1 Year: | 30.10% |
Compounded Profit Growth
| 5 Years: | 66.29% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -19.30% |
| 6 Months: | -21.65% |
| 3 Months: | -6.59% |
| 1 Month: | -0.30% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 32.83M | 7.74M | 15.18M | 9.21M | 47.58M | 34.31M | 48.60M | 54.58M | 118.69M | 153.24M | 205.61M | 243.71M | 273.00M | 353.66M | 432.72M | 487.97M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 186.87M | 205.63M | 212.78M | 247.44M |
| Cash & Equivalents | 16.49M | 17.00M | 14.12M | 31.25M | 5.53M | 13.64M | 8.06M | - | - | - | - | 18.29M | 26.89M | 33.62M | 68.33M | 51.07M | 69.09M | 74.52M | 100.09M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.99M | 13.09M | 17.37M | 17.56M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.54M | 58.36M | 61.38M | 84.63M |
| Total Liabilities | - | - | - | - | 20.71M | 5.67M | 5.32M | 11.94M | 12.18M | 23.89M | 32.04M | 16.46M | 42.15M | 71.35M | 73.24M | 80.73M | 127.70M | 140.75M | 133.33M |
| Current Liabilities | - | - | - | 29.86M | 20.67M | 5.66M | 5.32M | 11.83M | 12.11M | 12.85M | 13.09M | 14.79M | 19.80M | 22.48M | 26.05M | 37.46M | 45.75M | 50.29M | 49.15M |
| Long Term Debt | - | - | - | 41.00K | 40.00K | 6.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.57M | 88.04M | 98.97M | 96.37M |
| Total Equity | - | 16.75M | 14.78M | 2.92M | -12.97M | -32.10M | 3.89M | 35.64M | 22.13M | 24.71M | 22.54M | 102.23M | 111.09M | 134.26M | 170.46M | 192.27M | 225.95M | 291.97M | 354.64M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.25M | 47.83M | 49.63M | 50.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | -13.35M | -19.89M | -13.18M | -412.00K | -7.18M | 17.57M | - | 17.69M | 35.31M | 58.16M | 51.91M |
| Investing Cash Flow | - | - | - | - | - | - | -2.39M | -1.42M | -1.51M | -67.03M | 10.62M | -17.16M | - | -36.21M | -3.13M | -79.03M | -43.94M |
| Financing Cash Flow | - | - | - | - | - | - | -24.00K | 29.70M | 18.58M | 58.86M | 5.26M | 6.44M | - | 1.04M | 3.62M | 19.05M | 7.07M |
| Capital Expenditure | -35.00K | -120.00K | -1.03M | -273.00K | -40.00K | -829.00K | -2.43M | -1.42M | -1.51M | -2.68M | -2.62M | -2.63M | - | -7.60M | -27.51M | -63.97M | -27.16M |
| Free Cash Flow | - | - | - | - | - | - | -15.77M | -21.31M | -14.69M | -3.09M | -9.80M | 14.95M | - | 10.09M | 7.80M | -5.81M | 24.75M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.47M | 35.80M | -1.82M | 15.04M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2009 | Jun 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 47.9% | 53.5% | 64.6% | 68.1% | 69.1% | - | 66.8% | 68.6% | 72.6% | 74.4% |
| Operating Margin % | - | - | - | - | - | - | - | -35.4% | -23.9% | -4.3% | -9.5% | 1.9% | - | -10.4% | -3.3% | 1.9% | 4.0% |
| Net Margin % | - | - | - | - | - | - | - | -36.0% | -27.5% | -9.0% | -8.2% | 2.3% | - | -10.2% | -1.6% | 4.4% | 6.0% |
| ROE % | - | -98.5% | 151.6% | 91.8% | -401.2% | -55.9% | -73.8% | -79.2% | -76.7% | -8.0% | -8.7% | 2.1% | - | -8.7% | -1.4% | 3.5% | 4.7% |
| ROCE % | - | - | 224.6% | -354.7% | -538.4% | -65.8% | -75.1% | -53.8% | -36.1% | -3.8% | -8.4% | 1.3% | - | -7.2% | -2.1% | 1.2% | 2.5% |
Shareholding Pattern
Insiders
1.20%
Institutions
111.21%
Public Float
112.56%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.21% | 7.77M | $258.82M |
| 2 | State Street Corporation | 6.17% | 3.15M | $105.06M |
| 3 | Soleus Capital Management, L.P. | 4.99% | 2.55M | $84.96M |
| 4 | Conestoga Capital Advisors, LLC | 4.82% | 2.46M | $82.10M |
| 5 | Vanguard Capital Management LLC | 4.37% | 2.23M | $74.35M |
| 6 | William Blair Investment Management, LLC | 3.59% | 1.83M | $61.08M |
| 7 | BNP Paribas Asset Management Holding S.A. | 3.38% | 1.72M | $57.45M |
| 8 | Geneva Capital Management LLC | 3.22% | 1.65M | $54.89M |
| 9 | GW&K Investment Management, LLC | 3.17% | 1.62M | $53.89M |
| 10 | Congress Asset Management Co | 2.95% | 1.51M | $50.23M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VCEL
No recent headlines available.